← Back to Clinical Trials
Recruiting NCT07031843

NCT07031843 Exploration of a Novel Prognostic Prediction Model for Liver Cirrhosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07031843
Status Recruiting
Phase
Sponsor Juan Kang
Condition Cirrhosis
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2023-02-01
Primary Completion 2026-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2023-02-01 with a primary completion date of 2026-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The liver, a key organ for metabolism and synthesis, is involved in protein, fat, and carbohydrate metabolism, as well as energy production. Hepatic injury and functional decline can lead to metabolic abnormalities in these three major nutrients, as well as in vitamins and trace elements. Malnutrition, one of the most common complications in cirrhosis patients, has a broader impact than traditional complications like hepatic encephalopathy, esophageal variceal bleeding, refractory ascites, and spontaneous bacterial peritonitis. It is closely related to patient prognosis. Therefore, malnutrition should be considered as important as ascites and hepatic encephalopathy in diagnosis and treatment, and nutritional metabolism should be incorporated into prognostic prediction models or scoring systems for cirrhosis patients. Currently, the nutrition assessment of cirrhosis patients mostly uses relatively subjective methods such as scales and scores. There is no specific gold-standard diagnostic criterion for malnutrition in cirrhosis patients. Also, existing prognostic models for cirrhosis patients do not adequately consider the impact of nutritional factors on disease prognosis. Metabolomics technology can detect changes in the types and levels of nutritional metabolites in cirrhosis patients and analyze the differences in nutritional metabolites under various nutritional statuses and their relationship with the prognosis of cirrhosis patients. This helps objectively reveal the predictive value of nutrition metabolism for the prognosis of cirrhosis patients. However, metabolomics has been rarely used in nutrition assessment studies of cirrhosis patients and merits further research. This study will employ a prospective cohort study design to analyze the baseline nutritional status of patients with liver cirrhosis, investigate the impact of nutritional factors on long-term prognosis, and develop a prognostic prediction model for liver cirrhosis that incorporates nutritional parameters.

Eligibility Criteria

Inclusion Criteria: Participants must meet all of the following criteria to be eligible for this study. 1. Willingness and ability to sign the informed consent form. 2. Male or female, aged 18 to 75 years. 3. A diagnosis of liver cirrhosis that meets the reference criteria of the Chinese Society of Hepatology's "Guidelines for the Diagnosis and Treatment of Liver Cirrhosis". 4. An expected survival of over 3 months. 5. Full civil competence. Exclusion Criteria: 1. Primary liver cancer diagnosis, or supporting evidence of elevated alpha-fetoprotein (AFP≥100μg/L) for \>3 months, or imaging evidence of hepatic cancer nodules. 2. Malignancy history within 5 years before screening, except for specific cured cancers (e.g., basal cell skin cancer); current or past major illnesses (as defined by the China Insurance Regulatory Commission's 25 critical illnesses) that may affect treatment, assessment, or compliance. 3. Severe pulmonary, cardiac, diabetic, or genetic metabolic diseases. 4. Psychiatric hospitalization, suicide attempts, or temporary disability due to mental illness in the past 5 years. 5. Pregnant or breastfeeding women. 6. Individuals deemed unsuitable by the investigator.

Contact & Investigator

Central Contact

juan Kang, M.D.

✉ 68368892@qq.com

📞 +8613996112052

Principal Investigator

juan Kang, M.D.

STUDY CHAIR

The Second Affiliated Hospital of Chongqing Medical University

Frequently Asked Questions

Who can join the NCT07031843 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07031843 currently recruiting?

Yes, NCT07031843 is actively recruiting participants. Contact the research team at 68368892@qq.com for enrollment information.

Where is the NCT07031843 trial being conducted?

This trial is being conducted at Chongqing, China.

Who is sponsoring the NCT07031843 clinical trial?

NCT07031843 is sponsored by Juan Kang. The principal investigator is juan Kang, M.D. at The Second Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology